Time-dependent inhibition (TDI) of the cytochrome P450 (P450) family of enzymes is usually studied in human liver microsomes (HLM) by investigating whether the inhibitory potency is increased with increased incubation times. The presented work was initiated after a discrepancy was observed for the TDI of an important P450 enzyme, CYP3A4, during early studies of the investigational drug compound AZD3839 [(S)-1-(2-(difluoromethyl)pyridin-4-yl)-4-fluoro-1-(3-(pyrimidin-5-yl)phenyl)-1H-isoindol-3-amine hemifumarate]; TDI was detected using a regulatory method but not with an early screening method. We show here that the different solvents present in the respective studies, dimethyl sulfoxide (DMSO, screening method) versus methanol or water (regulatory method), were responsible for the different TDI results. We further demonstrate why DMSO, present at the levels of 0.2% and 0.5% in the incubations, masked the TDI effect. In addition to the TDI experiments performed in HLM, TDI studies with AZD3839 were performed in pooled human hepatocytes (Hhep) from different suppliers, using DMSO, methanol, or water. The results from these experiments show no TDI or attenuated TDI effect, depending on the supplier. Metabolite identification of the compound dissolved in DMSO, methanol, or water shows different profiles after incubations with the different systems (HLM or Hhep), which may explain the differences in the TDI outcomes. Thorough investigations of the biotransformation of AZD3839 have been performed to find the reactive pathway causing the TDI of CYP3A4, and are presented here. Our findings show that the in vitro risk profile for drug-drug interactions potential of AZD3839 is very much dependent on the chosen test system and the experimental conditions used.
Introduction
Inhibition of cytochrome P450 (P450) enzymes may lead to serious drug-drug interactions (DDIs), causing adverse drug effects (Wienkers and Heath, 2005) via either reversible or irreversible reactions (Murray, 1997; Lin and Lu, 1998) . Reversible inhibition means that two or more drugs compete at a P450-active site, and the perpetrating drug inhibits the interaction of other drugs with the P450 in a concentration-dependent manner. With irreversible inhibition, referred to as mechanism-based inhibition (MBI) or time-dependent inhibition (TDI), the P450 enzymes convert the drug to a reactive intermediate that inactivates the function of the P450 in a quasi-irreversible (metabolic intermediate complex to the heme) or irreversible way (Silverman, 1995; Lin and Lu, 1998) . MBI/TDI is thought to cause more serious DDIs than reversible inhibition as de novo synthesis of the inactivated protein is needed (Watanabe et al., 2007) . For these reasons, the potential of new chemical entities to cause DDIs via inhibition of P450 metabolism are studied preclinically and clinically during drug development. The most clinically relevant P450 enzyme in this regard is CYP3A4, which comprises about 30% of the total P450 content (Shimada et al., 1994) and is involved in the metabolism of more than 50% of the drugs on the market (Lehmann et al., 1998; Guengerich, 1999) .
Human liver microsomes (HLM) are the traditional enzyme system used for the study of P450 inhibition. Typically in drug discovery, a simple screening assay is used to identify and remove new chemical entities that cause unacceptable P450 inhibition; in the development phase, however, a more extensive study is conducted where regulatory authority recommendations guide the study design (Bjornsson et al., 2003; EMA draft DDI guideline, 2010; FDA draft DDI guidance, 2012) . The outcomes of the preclinical reversible inhibition studies (IC 50 and K I values) and TDI studies (K I and k inact values) are subsequently used for projection of possible DDIs in the clinic (Shardlow et al., 2011) . It has been shown that such simulations based on data obtained from HLM often overpredict the magnitude of DDIs compared with the actual observed interaction in vivo (Einolf, 2007; Chen et al., 2011) .
In recent years, several laboratories have developed P450 inhibition methods using human hepatocytes (Hhep), which represent a more complete system compared with HLMs because they contain both phase I and II enzymes and transporters, whereas HLM contain only phase I enzymes (Hewitt et al., 2007) . These differences could potentially alter the biotransformation of a compound and thus be the reason for different outcomes. The literature reports indicate that predictions of in vivo DDIs based on Hhep data might be more accurate than those that use HLM data (Xu et al., 2009; Chen et al., 2011; Kirby et al., 2011) .
Different experimental conditions may also be a factor that affects the biotransformation of a compound. It has been described that several organic solvents, such as dimethyl sulfoxide (DMSO), methanol, and acetonitrile reduce the activity of P450 enzymes, although various enzyme isoforms are differently susceptible to organic solvents. For example, DMSO inhibited CYP3A4-mediated reactions, even at low concentrations (0.1-0.2%), whereas methanol did not alter reactions present below 1%. CYP2C8/2C9-mediated conversions, however, were equally affected by DMSO and methanol (Chauret et al., 1998; Busby et al., 1999) . It has been recommended to keep the amount of organic solvents to a minimum and to use methanol or acetonitrile when possible. During screening activities in drug discovery, however, DMSO continues to be frequently used due to solubility considerations and other practicalities.
AZD3839 is an inhibitor of the b-secretase enzyme and is being developed for the treatment of Alzheimer's disease. It has recently entered phase 1 clinical studies. We discovered a discrepancy in the CYP3A4 TDI results for AZD3839, in which the discovery screening method found no TDI but a later regulatory method did. In the present work, we elucidate the reason for the discrepancy in the TDI results using HLM and cryopreserved Hhep. In addition, the biotransformation of AZD3839 has been thoroughly investigated in the different test systems and under various experimental conditions to elucidate the metabolic pathway and find the reactive metabolite(s) responsible for the observed TDI.
Materials and Methods

Chemicals and Reagents
AZD3839 [(S)-1-(2-(difluoromethyl)pyridin-4-yl)-4-fluoro-1-(3-(pyrimidin-5-yl) phenyl)-1H-isoindol-3-amine hemifumarate] and the metabolites M1 [(S)-5-(3-(3-amino-1-(2-(difluoromethyl)pyridin-4-yl)-4-fluoro-1H-isoindol-1-yl)phenyl) pyrimidine 1-oxide] and M2 [(S)-4-(3-amino-4-fluoro-1-(3-(pyrimidin-5-yl) phenyl)-1H-isoindol-1-yl)-2-(difluoromethyl)pyridine 1-oxide] were obtained from the Medicinal Chemistry department at CNSP iMed Science (AstraZeneca R&D, Södertälje, Sweden). (Fig. 1) was obtained from the Isotope Chemistry department at Global DMPK Screening and Profiling (AstraZeneca R&D). Midazolam, 19OH-midazolam, testosterone, 6b-OH-testosterone, 6b-OHtestosterone-D7, mifepristone, verapamil, troleandomycin, NADPH, reduced glutathione, potassium ferricyanide, and methoxylamine were all purchased from Sigma-Aldrich (St. Louis, MO). 19OH-midazolam and testosterone were also purchased from BD Biosciences (Bedford, MA) and Steraloids (Newport, RI), respectively. 13 C 3 -19OH-midazolam was purchased from Toronto Research Chemicals Inc. (Toronto, ON, Canada).
Test Systems
Pooled HLM were obtained from an AstraZeneca in-house pool (seven donors, mixed gender); purchased from Invitrogen (Carlsbad, CA), which were pooled from 87 livers (mixed gender); or purchased from BD Gentest (Woburn, MA), which were pooled from 33 and 150 donors (mixed gender). Hhep were purchased from CellzDirect [one male and two female donors (Durham, NC)] and KaLy-Cell [two male and 2 female donors (Plobsheim, France)]. Recombinant expressed human enzymes were obtained from BD Gentest (Woburn, MA).
Determination of Enzyme Kinetics in HLM
Various concentrations of [ 14 C]AZD3839 between 1 and 100 mM were incubated in triplicate in the presence of 0.25 mg microsomal proteins in 50 mM KPO 4 buffer, pH 7.4, at 37°C (final incubation volume, 100 ml). The incubations were initiated by the addition of NADPH at a final concentration of 1 mM and terminated after 10 minutes by addition of 100 ml of acetonitrile. The incubation times were chosen in the linear range in relation to amount of proteins and incubation time (data not shown). The control samples were incubated without NADPH. Precipitated proteins were removed by centrifugation at 3000 rpm for 15 minutes at 4°C, and acetonitrile was removed under a flow of nitrogen for 5 minutes at 37°C. The supernatants were transferred to vials and analyzed using restricted access media-liquid chromatographytandem mass spectrometry (LC-MS/MS) system.
Reversible CYP3A4 Inhibition by AZD3839 and Nitric Oxide Metabolites in HLM
The ability of AZD3839 to inhibit the activity of CYP3A4 was assessed using two typical CYP3A4 substrates, MDZ (2 mM) and TSN (50 mM), which were coincubated with AZD3839 (0.1, 0.3, 1, 3, 10, 30 and 100 mM) in triplicate and HLM at 0.01 mg/ml (MDZ) or 0.05 mg/ml (TSN) in the presence of 1 mM NADPH, 0.1 M phosphate buffer (pH 7.4), and 5 mM MgCl 2 at 37°C. The organic solvent was below 1%. The reactions were terminated by the addition of one volume of ethyl acetate after 3 minutes (MDZ) or 7 minutes (TSN), vortexed, and centrifuged at 3000 rpm for 5 minutes. The supernatants were transferred to new plates, evaporated to dryness under a stream of nitrogen, and reconstituted in 75 ml of mobile phase before analysis using LC-MS/MS according to the analytical parameters described in Table 1 . The inhibitory potency toward CYP3A4 was also investigated by incubating the AZD3839 N-oxide metabolites M1 and M2, in a competitive manner at various concentrations (0.5, 1, 3, 12.5, 30, 50 , and 100 mM, 0.5% methanol) at 37°C with midazolam (5 mM) or testosterone (50 mM), pooled HLM [0.05 (MDZ) or 0.1 mg/ml (TSN)], and NADPH (1 mM) for 5 minutes (MDZ) or 10 minutes (TSN). The reactions were terminated by the addition of one equal volume of ice-cold acetonitrile containing internal standard ( 13 C 3 -19OH-midazolam or 6b-OH-testosterone-D7). After centrifugation at 1600g for 10 minutes, the supernatants were analyzed by ultra-pressure liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) (Waters Corp., Milford, MA) according to the analytical parameters described in Table 1 .
TDI in HLM
K I and k inact Determination. To determine K I and k inact for the inactivation of CYP3A4, various concentrations of AZD3839 (0.5, 0.7, 1, 2.5, 5, 7.5, 12.5, 25, 30, 45, 50, 65, 75 , 100 mM, 0.5% methanol) or the positive control, verapamil (0.3, 1, 3, 10, 30, 65 , 100 mM), were preincubated with pooled HLM (0.5 mg/ml) for 10 minutes at 37°C. The reactions were initiated by NADPH (1 mM) to give a final volume of 100 ml. At the end of each preincubation period (3, 5, 10, 20, and 30 minutes) , an aliquot was transferred to prewarmed 50 mM KPO 4 containing MDZ [25 mM, corresponding to approximately 5 times the Michaelis-Menten constant (K m )] and NADPH (1 mM). A preincubation for 30 minutes without NADPH (denoted as 0 minutes) was also performed. The diluted samples were incubated for an additional 5 minutes before the reactions were terminated by the addition of an equal volume of ice-cold acetonitrile containing the internal standard, 13 C 3 -19OH-midazolam. After centrifugation at 1600 g for 10 minutes the supernatants were analyzed by UPLC-MS/MS according to the analytical parameters described in Table 1 .
Effect of Organic Solvents on TDI in HLM. To evaluate how the different solvents used for dissolving AZD3839 (DMSO, methanol, or water) affected the inactivation of CYP3A4 in TDI experiments, various concentrations of the compound [0.5, 1, 3, 12.5, 30, 50 , and 100 mM; final amount of solvent was 0 (water), 0.2, or 0.5%] were preincubated at 37°C for 10 minutes with pooled HLM at 0.5 (MDZ) or 1 mg/ml (TSN) before initiation of the reactions by addition of NADPH (1 mM) or 50 mM KPO 4 . At the end of the 30-minute preincubation period, fractions were diluted (10-fold) into incubation buffer (50 mM KPO 4 ) containing MDZ (25 mM) or TSN (300 mM, corresponding to 6 times K m ) and NADPH (1 mM). In addition to the 30-minute preincubations, longer preincubations (60, 90, and 120 minutes) were performed for incubations containing 0.5% DMSO before the 10-fold dilution into the substrate incubations (300 mM TSN). The diluted samples were incubated for 5 (MDZ) or 10 minutes (TSN) before the reactions were terminated by the addition of an equal volume of ice-cold acetonitrile containing internal standard ( 13 C 3 -19OH-midazolam or 6b-OH-testosterone-D7). After centrifugation at 1600g for 10 minutes, the supernatants were analyzed by UPLC-MS/MS according to the analytical parameters described in Table 1 .
Inhibition of CYP3A4 by AZD3839 Metabolites. The metabolites M1 and M2 were also incubated in a time-dependent manner at the same concentrations as previously described, with HLM at final concentrations of 1 mg/ml. After an initial preincubation for 10 minutes, the reactions were initiated by the addition of NADPH (1 mM) to give a final volume of 100 ml. At the end of each preincubation period (0, 30, and 60 minutes), an aliquot of 10 ml was transferred to pre-warmed 50 mM KPO 4 , TSN (300 mM), and NADPH (1 mM) (total volume of 100 ml). The diluted samples were incubated for 10 minutes before the reactions were terminated by the addition of an equal volume of icecold acetonitrile containing the internal standards (6b-OH-testosterone-D7). After centrifugation at 1600g for 10 minutes, the supernatants were analyzed by UPLC-MS/MS according to the analytical parameters described in Table 1 . In addition to the analysis of the probe substrate metabolites, the presence of metabolites of M1 and M2 was investigated by liquid chromatography mass spectrometry carried out on a LTQ Orbitrap hybrid Fourier transform mass spectrometer (Thermo Fisher Scientific, Waltham, MA) interfaced to an Accela HPLC pump (Thermo Fisher Scientific) and a CTC PAL autosampler (CTC Analytics, Zwingen, Switzerland). Electrospray in positive ion detection mode was used for ionization. The ion transfer line temperature and spray voltage were set to 300°C and 4.2 kV, respectively. The mass spectrometer was operated in full scan mode (m/z 150-1000) in combination with data-dependent product ion scanning of the most intense full-scan ions. Normalized collision energy was set to 35%. The mass spectrometric resolution was set to 30,000 in full-scan mode and 15,000 in data-dependent product ion scan mode. Chromatography was performed on a YMC Basic column (150 Â 4.6 mm, 3-mm particle size). The flow rate was 1 ml/min with a 1:20 split to the ion source and flow scintillation monitor (625 TR; PerkinElmer Life and Analytical Sciences, Waltham, MA). The mobile phase consisted of aqueous acetonitrile containing 0.1% formic acid and was programmed for a linear increase from 5 to 27% acetonitrile during a 50-minute period, the acetonitrile was thereafter increased to 100% during the next 5-minute period and was kept there for another 3 minutes before returning to the initial condition. Scintillation cocktail (Ultima Flo-M; PerkinElmer Life and Analytical Sciences) was pumped at a flow rate of 4 ml/min to the flow scintillation analyzer, which was equipped with a 0.5-ml flow cell.
TDI in Hhep
Pooled Hhep with three (CellzDirect) or four (KaLy-Cell) donors, at the cell density of 1 Â 10 6 cells/ml, were used to study the potential for AZD3839 to inhibit CYP3A4 activity. All suspensions were incubated in a humidified atmosphere of CO 2 /air (5%/95%) at 37°C. Preincubations were started with the addition of AZD3839 at various concentrations (2, 20, and 50 mM for CellzDirect hepatocytes, or 0.5, 1, 3, 12.5, 30, 50, and 100 mM for KaLy-Cell hepatocytes) and solvents to prewarmed hepatocytes. The final amount of solvent was 0.2% (DMSO or methanol) or no solvent present. As positive controls, mifepristone and troleandomycin were used. At the end of each preincubation period (0, 10, 30. and 60 minutes for CellzDirect hepatocytes or 0, 15, 30, 60, and 120 minutes for KaLy-Cell hepatocytes) a fraction was diluted 5 times into the substrate incubation containing MDZ at 30 mM. The diluted samples were further incubated for 15 minutes before the reactions were stopped by the addition of one equal volume of ice-cold acetonitrile containing internal standard. After centrifugation at 1600g for 10 minutes, the supernatants were analyzed by UPLC-MS/MS.
Mechanism of TDI
To investigate whether AZD3839 binds irreversible or quasi-irreversible to HLM proteins, AZD3839 at 50 mM (0.5% DMSO or 0.5% methanol) was incubated in duplicate with pooled HLM (1 mg/ml) with and without NADPH (5 mM) for 30 minutes before a 2-fold dilution to a second incubation (10 minutes) containing buffer (100 mM KPO 4 ) or Fe(CN) 6 . The enzyme activity was measured after another 2-fold dilution to a third incubation (15 minutes), containing NADPH (5 mM) and midazolam (10 mM). The metabolite 19OH-midazolam was quantified by LC-MS/MS, running in the positive electrospray ionization and MRM modes. Mifepristone and troleandomycin were used as control compounds for detection of irreversible (He et al., 1999) and quasi-irreversible inhibition (Lim et al., 2005) , respectively.
Metabolic profiling in HLM and Hhep
[ 14 C]AZD3839 dissolved in DMSO, methanol, or water at the final incubation concentrations of 5, 10, and 50 mM were incubated at 37°C for 0, 10, 30, and 60 minutes with HLM (0.5 mg/ml) and NADPH (1 mM) or Hhep (cell density of approximately 2 million cells/ml). All suspensions were incubated in a humidified atmosphere of CO 2 /air (5%/95%) at 37°C. The final amount of solvent was 0.5% (DMSO or methanol) or no solvent present. The reactions were terminated by the addition of one equal volume of ice-cold acetonitrile and centrifuged at 3800g for 10 minutes. The supernatants were transferred to new glass tubes, of which 25 ml was transferred to scintillation vials for measurement of total radioactivity. The rest was stored at -70°C until further used. Before analysis, the acetonitrile was evaporated from the supernatants from which 25 ml was transferred to scintillation vials for measurement of total radioactivity. The remaining supernatants were transferred to vials for LC/MS and flow scintillation analysis. For the analysis, 50 ml was injected.
Influence of Trapping Agents on the Biotransformation and TDI of AZD3839
To find the reactive metabolite(s) responsible for the CYP3A4 TDI, [
14 C] AZD3839 at 50 mM (0.5% DMSO, 0.5% methanol, or water) was incubated with pooled HLM (1 mg/ml), NADPH (1 mM) and reduced glutathione (GSH), potassium ferricyanide [Fe(CN) 6 ], or methoxylamine at 5 and 30 mM. The reactions were terminated at 0 and 30 minutes by the addition of an equal volume of ice-cold acetonitrile. After centrifugation at 1600g for 10 minutes, the acetonitrile was evaporated, and the remaining was analyzed by LC/MS and flow scintillation as previously described. The AZD3839 N-oxide metabolites M1 and M2 at 30 mM (0.5% methanol) were also incubated with pooled HLM (1 mg/ml), NADPH (1 mM), and 30 mM GSH for 0 and 30 minutes before termination by the addition of an equal volume of ice-cold acetonitrile. Sample work-up and analysis were performed as previously described. The effect of GSH on the CYP3A4 TDI effect was also investigated by preincubating AZD3839 at 0.5-100 mM (0.2% DMSO or 0.2% methanol) with pooled HLM (1 mg/ml), with and without NADPH (1 mM) and GSH (5 and 30 mM) for 30 minutes (after an initial preincubation period of 10 min prior to addition of NADPH). After the preincubation step, fractions were diluted (10-fold) into incubation buffer (50 mM KPO 4 ) containing TSN (300 mM) and NADPH (1 mM). The diluted samples were incubated for 10 minutes before the reactions were terminated by the addition of an equal volume of ice-cold acetonitrile containing the internal standard (6b-OH-testosterone-D7). After centrifugation at 1600g for 10 minutes, the supernatants were analyzed by UPLC-MS/MS according to the analytical parameters described in Table 1 .
Data Processing
IC 50 determination. Percentage of remaining activity was determined as compared with the activity of vehicle controls using eq. 1, where V (sample) is the reaction velocity of the sample, and Mean V (control) is the mean reaction velocity of the vehicle control.
K I and k inact . The apparent enzyme inactivation rate constant (k obs ) for each inhibitor concentration was obtained by plotting the logarithm of percent activity remaining versus preincubation time for each inhibitor concentration (I). The maximum inactivation rate constant (k inact ) and the inactivation constant that produces half the maximum enzyme inactivation rate (K I ) were determined by nonlinear regression by using the following equation (eq. 2). Data fitting was performed by using the software SigmaPlot for Windows (SigmaPlot 2001 version 7.00; SPSS ASC GmbH, Erkrath, Germany).
Fe(CN) 6 Displacement. The calculations were performed using eq. 3. At least 30% inhibition in buffer is required for the compound to be classified as a TDI compound. If % inhibition (buffer) 2 % inhibition [Fe(CN) 6 ] is greater than 20%, the compound is classified as a quasi-irreversible inhibitor. % inhibition ¼ 1 2 % control activity ðNADPHÞ % control activity ðno NADPHÞ Â 100 ð3Þ
Half-Life. The half-life (t 1/2 ) of AZD3839 was calculated in incubations with HLM where different solvents were present by using eq. 4, where k is the slope of the natural logarithm of percentage remaining versus incubation time.
Results
Determination of Enzyme Kinetics in HLM
AZD3839 was metabolized under initial rate conditions in HLM to two metabolites, nitric oxidation either in the pyrimidine ring (M1) or in the pyridine ring (M2) (Fig. 1) . The K m,app and V max values for the two N-oxides in HLM were obtained using the Michaelis-Menten plot: K m,app and V max were 2.0 mM and 217 pmol/min per mg (CL int = 108 ml/min per mg) for the formation of the metabolite M1, and 4.9 mM and 195 pmol/min/mg (CL int = 40 ml/min per mg), for the formation of the metabolite M2, respectively. Incubations with different recombinant expressed human enzymes indicated that CYP3A4 was the major enzyme responsible for metabolism of the compound. The contribution of CYP3A4 was estimated to be approximately 90% after compensation for abundance of different P450s in human liver. The formation of M1 and M2 from 5 mM AZD3839 in HLM was nearly completely blocked by 1 mM of the specific CYP3A4 inhibitor ketoconazole. Wang et al. (2005) showed that the metabolite retrorsine-N-oxide could be reduced back to its parent compound in HLM. The N-oxide metabolites, M1 and M2, however, were not converted back to AZD3839 in HLM under the experimental conditions used (data not shown). Table 2 .
TDI of CYP3A4 by AZD3839 and N-Oxide Metabolites in HLM
AZD3839 is a potent time-dependent inhibitor of CYP3A4 in vitro, with K I and k inact values determined to be 0.58 6 0.14 mM and 0.025 6 0.003 min 21 (N = 3), using MDZ as a probe substrate (Fig. 2A) . The inhibition parameters for the positive control verapamil (Fig. 2B ), K I = 2.23 6 0.08 mM and k inact = 0.035 6 0.001 min
21
, were of similar magnitude as reported elsewhere (Wang et al., 2004; Chen et al., 2011) .
The influence of organic solvents on TDI of CYP3A4 was examined by comparing IC 50 curves of AZD3839 at 0 and 30 minutes preincubation times with DMSO and methanol at 0.2 and 0.5% or only water present (TSN as probe substrate). When AZD3839 was dissolved in 0.2 or 0.5% methanol or in water a .5-fold shift in the IC 50 curves was detected between 0 and 30 minutes preincubation times, which is indicative for TDI (Fig. 3, A and B) . No shift occurred when 0.2 or 0.5% DMSO was present in a similar experimental setup (Fig. 3C) . However, when preincubation times were prolonged to 60-, 90-, and 120-minute time-dependent shifts in the IC 50 curves were observed in the presence of 0.5% DMSO (Fig. 3D) . Similar results were found when using MDZ as CYP3A4 probe substrate (data not shown).
To further elucidate which P450 reaction was responsible for the TDI of CYP3A4, incubations were prepared with M1 and M2 using methanol. Shifts in the IC 50 curves for both M1 and M2 at the preincubation times of 0, 30, and 60 minutes were observed. In Fig. 4 , the curves are presented with TSN as CYP3A4 probe substrate. The same pattern was observed with MDZ (data not shown).
TDI in Hhep
In Hhep from CellzDirect, a concentration-dependent inhibition was observed of the CYP3A4 activity, but no TDI. The results were similar independently of solvent used (Fig. 5) . However, in the Hhep from KaLy-Cell, TDI was detected, with K I and k inact determined to be 2.81 mM and 0.01 min 21 , respectively (Fig. 6) .
Mechanism of TDI
When 50 mM AZD3839 was dissolved in 0.5% DMSO, only 25% inhibition of CYP3A4 was observed in buffer in the Fe(CN) 6 displacement experiment (Fig. 7) . This was consistent with the previous HLM experiments in which AZD3839 was not identified as a time-dependent inhibitor of CYP3A4 in the presence of DMSO. However, when AZD3839 was dissolved in 0.5% methanol, 50% reduction of the CYP3A4 activity was observed, which classified the compound as a time-dependent inhibitor. Addition of Fe(CN) 6 only reversed 12% of the lost P450 activity, showing that the nature of binding was irreversible. Troleandomycin and mifepristone are characterized as quasi-irreversible and mechanism-based inhibitors, respectively (He et al., 1999; Lim et al., 2005; Fontana et al., 2005) , and were used as control compounds. The addition of Fe(CN) 6 reversed the CYP3A4-inhibiting effect of troleandomycin but not of mifepristone, which was in line with our expectations.
Metabolic Profiling in HLM and Hhep
The N-oxide metabolites, M1 and M2, were the major metabolites from AZD3839 in HLM. These metabolites were generated independently of solvent used (i.e., DMSO, methanol, or water). However, a quantitative difference was present: less M1 and M2 was formed in the presence of DMSO (Fig. 8A ) compared with methanol (Fig. 8B) or water (Fig. 8C) . The half-life for AZD3839 (10 mM) in the incubations containing DMSO was approximately 6.5 hours compared with approximately 2-2.5 hours in the incubations containing methanol or water.
The metabolic profile of AZD3839 in Hhep was different from HLM. The major metabolite in the Hhep from CellzDirect was M23 (Figs. 1 and 9) , which was not present in HLM. There was no quantitative difference depending on solvent present (Fig. 9, A and B) . M1 and M2 were also present but to a much lesser extent compared with HLM. In Hhep from KaLy-Cell (Fig. 9C) , there was very little turnover, and M23 was present only as trace (,1%).
Influence of Trapping Agents on the Biotransformation and TDI of AZD3839
The production of M1 and M2 from [ 14 C]AZD3839 in HLM in the presence of 5 mM GSH, Fe(CN) 6 or methoxylamine was diminished. The metabolites totally disappeared in the presence of 30 mM GSH, Fe(CN) 6 or methoxylamine. No adducts could be detected with any of the trapping agents in spite of the demonstrated TDI. The same pattern was observed when M1 and M2 were incubated with GSH (5 and 30 mM). Conversion of M1 to M23 and of M2 to M9 decreased in the presence of 5 mM GSH and disappeared at 30 mM GSH. The CYP3A4 TDI effect (IC 50 shift) by AZD3839 (0.2% methanol) in the presence of GSH disappeared (Fig. 10A) . Analysis of the formed dmd.aspetjournals.org metabolites from those incubations revealed that M1, M2, and M9 were formed in the absence of GSH, and that M2 decreased and M9 disappeared in the presence of GSH. Consistent with other results, no TDI was observed when AZD3839 was dissolved in DMSO (0.2%), and the GSH did not affect this result (Fig. 10B) . From the metabolic profile (MS-data), M1 and M2 were formed but no M9 in the incubations where DMSO was present.
Discussion
The BACE1 inhibitor AZD3839 is a compound that is under development for the treatment of Alzheimer's disease. Because patients with the disease are meant to be treated chronically with AZD3839 and are using other medications concomitantly, potential DDIs are important to consider. The assessment of the DDI potential of AZD3839 is rather complex. The high dependency on CYP3A4 leads to a high risk for DDIs with other CYP3A4 drugs. Moreover, AZD3839 and its metabolites M1 and M2 inhibited CYP3A4 in a reversible and an irreversible manner, which could affect not only the metabolism of other CYP3A4 substrates but also the metabolism of AZD3839 itself.
Predictions based on the in vitro TDI data generated in HLM using methanol or water indicated that AZD3839 was expected to be a potent in vivo inhibitor of CYP3A4 and to have strong interactions with other CYP3A4 substrates, such as MDZ or simvastatin [median 9-fold increase in area under the curve (AUC)]. No interaction with 200 mg of ketoconazole was predicted (median 1.2-fold increase in AUC) because CYP3A4 already was nearly maximally inhibited by AZD3839. On the basis of the P450 inhibitory data with DMSO, however, the risk profile for AZD3839 with respect to expected DDIs was reversed: no interaction potential with MDZ or simvastatin is expected, but an interaction was predicted with coadministration of 200 mg of ketoconazole (median 2.5-fold increase in AUC).
From the AZD3839 metabolite identification experiments in HLM, we observed that there was a quantitative difference in the metabolites formed, depending on solvent; less M1 and M2 was formed in DMSOcontaining incubations compared with methanol-or water-containing incubations under the same incubation time as a consequence of the reduced CYP3A4 activity. The same phenomenon was observed by Nishiya et al. (2010) , who studied TDI of CYP3A4 by diazepam dissolved in methanol, acetonitrile, or DMSO. They observed that the formation of the metabolites of diazepam decreased when the substrate was dissolved in DMSO compared with methanol and acetonitrile, and the TDI was attenuated. However, TDI of AZD3839 in 0.5% DMSO was observed when the preincubation times for AZD3839 were prolonged to 60, 90, and 120 minutes. This suggests that that there is a quantitative relationship between the metabolites formed in HLM and the TDI effect observed. DMSO reduced the formation of reactive species of AZD3839 that cause TDI of CYP3A4. This finding is further strengthened by the observation that also trapping agents attenuated the metabolic conversion of AZD3839 and abolished TDI. It is well known that DMSO inhibits CYP3A4 (Chauret et al., 1998; Busby et al., 1999) . It should be recognized that DMSO is an oxidizable solvent, and the amount of 0.2% corresponds to approximately 30 mM, which is a high substrate concentration; however, we had not anticipated to observe this dramatic difference in the TDI results at these amounts that cause approximately 30% reduction in CYP3A4 activity (Chauret et al., 1998; Busby et al., 1999) . These results further strengthen that the enzyme-inhibiting effect of DMSO, even at low amounts, should be considered when performing metabolism studies when DMSO-sensitive enzymes are involved. Apart from the discrepancies in TDI results, we also discovered that the clearance and half-life predictions of AZD3839 from HLM were solvent-dependent. The half-life observed when DMSO was present in the incubations was approximately twice as long as that observed with methanol. This could be relevant when predicting human clearance based on in vitro test systems. To prevent false TDI negative results, use of DMSO should be avoided in the assessment of DDI compounds in early clinical development.
Lately, laboratories have developed P450 inhibition methods using Hhep as a complement to studies in HLM (Lu et al., 2008; Mao et al., 2011) . We observed that the TDI results with AZD3839 in a typical TDI experiment was dependent on the supplier of the hepatocytes. No TDI could be detected from IC 50 shift experiments performed in Hhep from CellzDirect. In Hhep from KaLy-Cell, TDI was detected, although the K I value was less potent compared with HLM. This attenuated TDI effect in Hhep compared with HLM has been observed elsewhere (Chen et al., 2011) and is probably due to lower intracellular concentration of the inhibitor caused by nonspecific binding, metabolite consumption, or active transport. Incubations of AZD3839 in HLM were also 2-fold more diluted during the TDI determination than in Hhep incubations. Theoretically, higher remaining concentrations of AZD3839 in Hhep incubations could retain some effects. However, AZD3839 showed no competitive inhibition in Hhep, and the magnitude of TDI in Hhep was reduced rather than increased. Therefore, it is unlikely that lesser dilution has had a significant impact on the TDI determination of AZD3893 in Hhep. When the metabolic profiles of AZD3839 were investigated in Hhep, it was observed that also the biotransformation of AZD3839 was different depending on supplier of Hhep but also compared with HLM. In Hhep from CellzDirect, the major metabolite was M23; in Hhep from KaLy-Cell, M23 was only present in trace amounts. M23 was not present in HLM at all. M1 and M2 were generated in Hhep but to a lesser extent compared with HLM. Interestingly, there was no quantitative difference in metabolite formation depending on solvent It has been shown that in vivo DDI predictions based on data obtained with Hhep give a better correlation to clinical outcomes than predictions derived from HLM data, which tend to overpredict (Xu et al., 2009; Chen et al., 2011; Kirby et al., 2011) . The differences in the TDI results observed for AZD3839 between the two hepatocyte suppliers make it difficult to conclude which data to use for predictions of in vivo DDI. It reveals the uncertainty that is associated with these projections based on relatively simple test systems. If a compound shows different metabolic pathways between HLM and Hhep, it could be useful to use Hhep in parallel to HLM, but additional studies and insight are needed before using Hhep as the first choice of enzyme systems for studying TDI, particularly if results are dependent on the supplier.
From a Fe(CN) 6 displacement study, it was shown that AZD3839 was an irreversible inhibitor. We did not detect any adducts, but the trapping agents affected the biotransformation of AZD3839 in such way that the production of the major metabolites, M1 and M2, decreased in the presence of a trapping agent (5 mM ) and disappeared totally in the presence of 30 mM. This inhibiting effect of trapping agents was also shown by Zhang et al. (2009) , who observed that GSH above 1 mM leveled off the amount of GSH adduct of the imine methine metabolite of 3-methylindole, which could indicate a potential P450 inhibition by GSH. In addition, methoxylamine was also shown to be an inhibitor of CYP3A4 at the lower millimolar concentrations. The inclusion of trapping agents to the HLM incubations with AZD3839 also affected the results in such way that no TDI was observed in the presence of GSH. This protection against TDI together with the inhibiting effect of the generation of M1 and M2 by GSH strongly suggests that the reactive metabolic pathway causing the CYP3A4 TDI in HLM goes via these two metabolites. The fact that also M1 and M2 themselves are causing TDI may point to a subsequent metabolic conversion of these N-oxides that gives rise to reactive species.
In summary, we have discovered that the presence of DMSO in incubations, even at the low amount of 0.2%, masked the TDI of CYP3A4 by AZD3839 in a standard 30-minute preincubation method in HLM. When prolonging the preincubation times to or longer than 60 minutes, TDI was observed. The reason for lack of TDI at the 30-minute preincubation is probably because of a CYP3A4-inhibiting effect of DMSO. The major metabolic pathways of AZD3839 via M1 and M2 in HLM seemed to be responsible for the TDI observed, as both metabolites inhibited CYP3A4 in a competitive and timedependent manner, and reduction of formation of these metabolites by trapping agents prevented TDI. The sensitivity toward DMSO was not prominent in Hhep, where the amount of metabolites of AZD3839 was equal between incubations with water or DMSO present. However, different metabolic profiles and TDI results were observed from the different batches of Hhep, with no TDI detected in one batch and some inhibition, albeit less potent than that seen with HLM, in another. These findings show that the in vitro risk profile for DDI potential is very much dependent on the chosen test system and the experimental conditions. More investigations are required to evaluate the potential of hepatocytes as an in vitro system for DDI predictions. 
